The introduction of the drug in the country is generating significant buzz within the medical community. This novel dual agonist – targeting both GLP-1 and GIP receptors – offers a potentially effective option for https://bpc157australia432857.stilblogger.com/476533/australia-s-retatrutide-australia-a-possible-promising-hope-for-weight-control